Key facts
- It has raised $1.4M; the latest was Early Stage VC ($1.4M) in Jul 2025.
- Notable investors include Connecticut Innovations.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Capehaven
- ·The full record, as it builds
Funding rounds
No funding rounds for Capehaven are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Capehaven
Operator of a biotech venture creation firm intended to bridge the gap between academic discoveries to commercialization. The company specializes in advancing early-stage therapeutics from academia to a financeable business, enabling clients to deliver life-saving therapies to patients in need.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2025
- Website
- capehavenbio.com/
- Ownership
- Privately Held (backing)
Capehaven doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Capehaven shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Capehaven in its N-PORT filings yet. We sweep new filings monthly.